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Purpose: The selective cyclooxygenase-2 inhibitor lumiracoxib
has been shown to reduce endoscopically detected ulcers and
ulcer complications in the upper gastrointestinal tract compared
with non-selective non-steroidal anti-inﬂammatory drugs. We in-
vestigated whether lumiracoxib would reduce small bowel injury
compared with naproxen plus omeprazole.
Methods: Healthy volunteers were randomized to receive lu-
miracoxib 100 mg once daily, naproxen 500 mg twice daily plus
omeprazole 20 mg once daily or placebo in a 16-day double-
blind, parallel-group study. Small bowel mucosal injury and in-
ﬂammation were assessed by video capsule endoscopy (VCE),
the lactulose:rhamnose permeability assessment, and the faecal
calprotectin test.
Results: Of 152 randomized subjects, 139 completed the study
with valid VCEs (lumiracoxib, n = 47; naproxen plus omepra-
zole, n = 45; placebo, n = 47). Compared with placebo, an
increased number of subjects on naproxen plus omeprazole
had small bowel mucosal breaks (77.8% vs 40.4%, P<0.001),
with increased permeability (P=0.023) and raised faecal calpro-
tectin (increase of 96.8 mg/kg vs 14.5 mg/kg placebo, P<0.001).
With lumiracoxib, 27.7% of subjects had small bowel mucosal
breaks (P=0.196 vs placebo;P<0.001 vs naproxen), there was
no increase in permeability (P=0.157 vs placebo;P=0.364 vs
naproxen) and no increase in faecal calprotectin (-5.7 mg/kg;
P=0.377 vs placebo; P<0.001 vs naproxen).
Conclusions: As assessed by three different measures, acute
small bowel injury on lumiracoxib treatment is less frequent than
with naproxen plus omeprazole and similar to placebo.
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Purpose: Matrix associated transplantation techniques aim to
improve autologous chondrocyte implantation as introduced by
Brittberg. At the Medical University of Vienna, Department of
Orthopedics Hyalograft C, a bio scaffold based on hyaluronan
was used for autologous chondrocyte transplantation.
Methods: 53 patients were treated with Hyalograft C in the knee
joint. 31 were male, 22 female, 50 had single defects, 3 had
multiple defects. Mean age at implantation was 32 SD 12 years,
mean defect size was 4.4 SD 1.9 cm2, the mean BMI was 24.5
SD 3.8. 41 cases showed defects on the medial femoral condyle
(MFC), 6 cases on the lateral femoral condyle (LFC). 2 had
patellar defects, 1 tibial, 1 MFC/LFC, 1 tibial/MFC and in one
case multiple defects on the MFC were treated.
The primary indication for Hyalograft concerned young patients
with stable ligaments, regular knee alignment and singular de-
fects with healthy adjacent cartilage. During the ﬁrst two years,
implantation was also performed in eight salvage cases.
A biopsy for cell culture was harvested during ﬁrst look
arthroscopy. Cell expansion and scaffold seeding was carried
out by FIDIA Advanced Biopolymers, Abano Terme, Italy. Im-
plantation was carried out in arthroscopy and in miniarthrotomy.
We used three knee scoring systems for clinical follow up: the
Lysholm Score, a modiﬁed Cincinnati Knee Score and the IKDC
Subjective Knee Form.
For MRI evaluation we used an isotrope fat-supressed 3D GRE
sequence on a 3.0 T MRI unit (Siemens, Tim Trio).
For statistical evaluation we used bivariate correlation analysis
and unpaired, two-tailed t-tests.
Results: Cumulative evaluation demonstrated an improvement
below the level of signiﬁcance of p<0.001 in all scores (Table 1).
Table 1. Mean ± SD cumulative outcome of various scores
Before surgery 5 years after implantation
Modiﬁed Cincinnati Score 2.7±1.4 7.1±2.4
IKDC Subjective Knee Form 40.5±19.2 66.1±18.9
Lysholm Score 57.6±16.9 85.0±19.4
MRI at ﬁve years was available in nine cases and demonstrated
repair tissue (RT) in situ in all patients. The ﬁlling grade was
complete in 5 patients, 4 had a ﬁlling grade over 50%. Integration
with surrounding cartilage was complete in all cases. RT surface
was intact in 6 patients, minor ﬁbrillations were found in 3 cases.
RT was homogenous in 6 cases. We found minor bone marrow
edema in 3 patients. Joint effusion was absent in all cases. A
representative example for good outcome is shown in Fig. 1.
Figure 1. Repair tissue (RT) on the dorsal aspect of the medial femoral condyle
5 years after implantation (white arrows) with a complete ﬁlling of the defect,
excellent integration with surrounding cartilage and intact RT surface, homoge-
nous RT signal as well as isointense signal intensity. The subject is an active
runner, routine training comprised 80 kilometers per week before a traumatic
lesion of the meniscus (black arrow) occurred.
Spearman’s rho of age and the clinical improvement in the
Lysholm Score after one year was -0.449 (p = 0.006).
7 of 8 salvage patients underwent a total replacement of the
knee joint due to persisting pain between 2 and 5 years after im-
